Prevalence of hypertensive disorders during pregnancy in France (2010-2018): The Nationwide CONCEPTION Study
- PMID: 34042277
- PMCID: PMC8678732
- DOI: 10.1111/jch.14254
Prevalence of hypertensive disorders during pregnancy in France (2010-2018): The Nationwide CONCEPTION Study
Abstract
Hypertensive disorders of pregnancy (HDP) are one of the leading causes of maternal and fetal morbidity and mortality. We aimed to estimate the prevalence of each HDP in France and to study their associations. All pregnant women who delivered in France between 2010 and 2018 were included in a cohort and followed during their pregnancy and 6 weeks of postpartum. Each HDP occurring during the follow-up was identified. Prevalence of each HDP and cumulative incidence by gestational age were estimated. Incidence rate ratio (IRR) and 95% confidence interval (CI) for preeclampsia among women with preexisting or gestational hypertension (GH) were estimated using Poisson regression and adjusted for age were estimated. Between 2010 and 2018, 6 302 810 deliveries were included. HDP complicated 7.4% of pregnancies. Preeclampsia and GH complicated 2.0% and 4.2% of pregnancies, respectively. Most of preeclampsia cases occurred without a prior HDP. HELLP syndrome represented 10.4% of preeclampsia cases. Compared to nulliparous pregnancies without HDP prior preeclampsia, the age-adjusted IRR of preeclampsia was 6.2 [95% CI: 6.1-6.4] in nulliparous pregnancies with preexisting hypertension and 2.9 [95% CI: 2.8-3.0] in nulliparous pregnancies with GH. In France, HDP occurred in 7.4% of all pregnancies. Women with preexisting chronic hypertension are at high risk to present preeclampsia during pregnancy. Preeclampsia complicated 2.0% of pregnancies in France. Tailoring management of women according to the HDP is a major challenge to avoid complications related to these disorders.
Keywords: France; HELLP syndrome; gestational hypertension; preeclampsia; prevalence.
© 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Conflict of interest statement
VO, AG, CG, GPB, CDT, EM, VT, and NR have nothing to disclose. SK reports, outside the submitted work, non‐financial support from Lilly France, Novonordisk, Novartis pharma, Roche diabetes care, Lifescan, Abbott france, Sanofi, ViiV healthcare, Servier, Becton Dickinson and personal fees from icomed, Pascaleo, BT3SI, M3global research. CMV reports, outside the submitted work, personal fees and non‐financial support from Servier, Lundbeck, Astrazeneca, MSD, Boehringer. JB reports, outside the submitted work, personal fees from Abbott, Bayer, Bottu, Egis, Ferring, Steripharma, Kantar, Teriak personal fees and non‐financial support from Pfizer, Quantum Genomics, personal fees from Sanofi, Servier.
Figures
References
-
- Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre‐eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391‐403. - PubMed
-
- Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All hypertensive disorders of pregnancy increase the risk of future cardiovascular disease. Hypertension. 2017;70(4):798‐803. - PubMed
-
- Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res. 2017;40(3):213‐220. - PubMed
-
- Panaitescu AM, Ciobanu AM, Popescu MR, et al. Incidence of hypertensive disorders of pregnancy in Romania. Hypertens Pregnancy. 2020;39(4):423‐428. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
